Clinical Trials Browser

Phase 2 × OTHER × Fibroblast Growth Factor 7 × Clear all

NCT01746849 2026-01-07

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2 Active not recruiting

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT01746173 2023-01-30

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Phase 2 Terminated

5 enrolled 7 charts

Lymphoma, T-Cell

NCT01237951 2020-05-05

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Phase 2 Completed

75 enrolled 11 charts

Neoplasms, Plasma Cell

NCT01200329 2019-12-16

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Phase 2 Completed

81 enrolled 8 charts

Hodgkin Disease, Lymphoma, Recurrence

NCT00593554 2018-04-10

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Phase 2 Terminated

9 enrolled 13 charts

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Phase 2 Withdrawn

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00267046 2012-05-16

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Phase 2 Completed

49 enrolled 7 charts

Sarcoma, Stomatitis